Holen Sie sich die Stockscreener-App
16.68
0.60%
-0.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$16.78
Offen:
$16.49
24-Stunden-Volumen:
6.51M
Relative Volume:
0.66
Marktkapitalisierung:
$8.61B
Einnahmen:
$11.24B
Nettoeinkommen (Verlust:
$-900.00M
KGV:
-9.9345
EPS:
-1.679
Netto-Cashflow:
$323.00M
1W Leistung:
+0.06%
1M Leistung:
-15.29%
6M Leistung:
-28.20%
1J Leistung:
-50.43%
1-Tages-Spanne:
$16.31
$17.04
1-Wochen-Bereich:
$15.73
$17.20
52-Wochen-Spanne:
$15.73
$33.60
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
16.68 | 8.61B | 11.24B | -900.00M | 323.00M | -1.679 |
ISRG
Intuitive Surgical Inc
|
452.07 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.51 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.56 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.28 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
224.09 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
How Investors May Respond To Baxter International (BAX) Expanding Into Automated IV Line Labeling Systems - Yahoo Finance
Does Baxter’s New IV Verify Labeling System Redefine Its Automation Edge In Healthcare Workflow Efficiency (BAX)? - simplywall.st
BAXTER INTERNATIONAL INC. R (BTL.HM) Q2 FY2025 earnings call transcript - Yahoo Finance
Baxter International unveils IV Verify to enhance IV labeling accuracy - MSN
Columbia Intrinsic Value Fund's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter’s IV Verify Launch Tests Medication Safety Strategy And Hospital Traction - simplywall.st
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International Introduces IV Verify to Improve the Precision of IV Labeling - Bitget
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy - Yahoo Finance
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings - BioSpace
Pet Partners, Baxter Foundation Expand Therapy Animal Programs for Patients, Healthcare Workers - Pet Age
Baxter (BAX) Unveils New IV Verify Line Labeling System for Nurs - GuruFocus
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Baxter International Hits New 52-Week Low at $15.87 - Markets Mojo
Baxter International Inc (BAX) Stock Price Down 4.2% on Mar 30 - GuruFocus
Baxter launches IV labeling system aimed at improving safety, efficiency - Medical Economics
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot - Bioscience Association Manitoba
Baxter debuts automated IV line labeling system By Investing.com - in.investing.com
Baxter debuts automated IV line labeling system - Investing.com
Baxter stock price forecast: bearish trend persists as BAX trades near 52-week lows - Traders Union
Baxter Foundation Therapy Animal Push And What It Means For Investors - simplywall.st
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter International (NYSE:BAX) Hits New 1-Year LowTime to Sell? - MarketBeat
Baxter International stock hits 52-week low at 16.07 USD By Investing.com - Investing.com Australia
Baxter International stock hits 52-week low at 16.07 USD - Investing.com
BAX SEC FilingsBaxter Intl Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical Nutrition for Cancer Care: 2026-2030 Market - GlobeNewswire
Clinical Nutrition for Cancer Care: 2026-2030 Market Analysis Featuring Profiles of Leading PlayersAbbott Nutrition, Baxter International, B Braun Melsungen, Nestle Health Science, Danone Nutricia and More - Yahoo Finance UK
Bank of America maintains a hold rating on Baxter International (BAX) - MSN
Baxter International Stock: Navigating Leadership Changes and Portfolio Optimization Amid Market Pre - AD HOC NEWS
Bank of America Maintains a Hold Rating on Baxter International (BAX) - Insider Monkey
A Look At Baxter International (BAX) Valuation As CFO Transition Draws Investor Attention - simplywall.st
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
[SCHEDULE 13G/A] BAXTER INTERNATIONAL INC Amended Passive Investment Disclosure - Stock Titan
SG Americas Securities LLC Has $32.97 Million Stock Position in Baxter International Inc. $BAX - MarketBeat
Baxter to Host Annual Meeting of Stockholders in Virtual Format - marketscreener.com
Baxter investors get online-only annual meeting, with voting on May 5 - Stock Titan
Baxter International stock faces pressure from ifosfamide shortage and reduced production capacity a - AD HOC NEWS
Manufacturing Disruption Hits Baxter Cancer Drug Supply In Europe - sahmcapital.com
Therapy animals will reach 100,000 patients and care teams in pilot - Stock Titan
EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks - Benzinga
Revenue of Baxter International from 2021 to 2025 - Statista
EU regulator flags Baxter cancer drug shortage until early next year - KELO-AM
Baxter International Stock Hits Day Low of $16.08 Amid Price Pressure - Markets Mojo
Baxter International Inc. stock faces pressure from EU cancer drug shortage warning until early 2027 - AD HOC NEWS
Baxter says production of ifosfamide resumed, but at reduced capacity that does not meet current demand - marketscreener.com
The Bull Case For Baxter International (BAX) Could Change Following CFO Turnover And FTSE Index Removal - simplywall.st
EU regulator warns of shortage in Baxter's cancer treatment until early 2027 - marketscreener.com
Baxter International Opens Weak with 6.19% Gap Down Amid Market Concerns - Markets Mojo
Baxter International Hits New 52-Week Low at $16.08 - Markets Mojo
Baxter International : 2025 Proxy Statement - marketscreener.com
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):